FY2019 EPS Estimates for Medpace Holdings, Inc. Raised by William Blair (MEDP)

Medpace Holdings, Inc. (NASDAQ:MEDP) – Analysts at William Blair increased their FY2019 EPS estimates for Medpace Holdings in a note issued to investors on Tuesday. William Blair analyst J. Kreger now anticipates that the company will post earnings per share of $1.90 for the year, up from their prior estimate of $1.80. William Blair also issued estimates for Medpace Holdings’ FY2020 earnings at $2.17 EPS.

MEDP has been the subject of several other research reports. Jefferies Group LLC reiterated a “hold” rating and issued a $25.50 price target (down previously from $35.50) on shares of Medpace Holdings in a research report on Wednesday, May 3rd. Wells Fargo & Company downgraded shares of Medpace Holdings from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 3rd. ValuEngine downgraded shares of Medpace Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Zacks Investment Research downgraded shares of Medpace Holdings from a “hold” rating to a “strong sell” rating in a research report on Friday, May 5th. Finally, Credit Suisse Group restated an “outperform” rating and set a $36.00 price objective (up previously from $35.00) on shares of Medpace Holdings in a research report on Tuesday, June 6th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $34.00.

Medpace Holdings (NASDAQ MEDP) traded up 0.32% on Friday, hitting $31.63. 149,999 shares of the company’s stock were exchanged. The company has a market cap of $1.25 billion and a PE ratio of 55.69. Medpace Holdings has a 12-month low of $21.76 and a 12-month high of $38.94. The company’s 50-day moving average price is $28.44 and its 200-day moving average price is $29.49.

Medpace Holdings (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, July 31st. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.08. The business had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $92.71 million. Medpace Holdings had a net margin of 5.37% and a return on equity of 9.32%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company posted $0.45 earnings per share.

A number of institutional investors have recently made changes to their positions in the company. Bernzott Capital Advisors increased its position in shares of Medpace Holdings by 141.4% in the second quarter. Bernzott Capital Advisors now owns 593,840 shares of the company’s stock worth $17,221,000 after buying an additional 347,804 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Medpace Holdings during the first quarter worth approximately $9,888,000. Granite Investment Partners LLC purchased a new position in shares of Medpace Holdings during the second quarter worth approximately $8,118,000. Massachusetts Financial Services Co. MA increased its position in shares of Medpace Holdings by 47.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 452,555 shares of the company’s stock worth $13,509,000 after buying an additional 144,815 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Medpace Holdings by 12.4% in the first quarter. Vanguard Group Inc. now owns 822,842 shares of the company’s stock worth $24,562,000 after buying an additional 90,742 shares during the last quarter. Institutional investors own 16.82% of the company’s stock.

About Medpace Holdings

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.